Table 2

Performance of baseline anti-HBc level in predicting HBeAg seroconversion in Peg-IFN and NUC cohorts

CohortsCut-off valuesSensitivity (%)Specificity (%)PPV (%)NPV (%)LR+LR
Peg-IFN≥4.087.926.547.374.51.200.46
≥4.183.837.150.075.41.330.44
≥4.272.746.250.369.31.350.59
≥4.368.753.852.769.61.490.58
≥4.460.666.757.769.31.820.59
≥4.546.574.257.564.91.800.72
NUC≥4.090.530.729.790.91.310.31
≥4.184.737.830.688.41.360.41
≥4.273.049.431.885.01.440.55
≥4.358.459.331.781.51.440.70
≥4.448.968.833.780.61.570.74
≥4.537.279.036.479.51.770.80
Overall≥4.089.429.735.186.81.270.36
≥4.184.337.736.585.01.350.42
≥4.272.948.637.680.81.420.56
≥4.362.758.038.878.51.490.64
≥4.453.868.341.977.71.700.68
≥4.541.177.844.175.71.850.76
  • anti-HBc, hepatitis B core antibody; HBeAg, hepatitis B e antigen; LR, negative likelihood ratio; LR+, positive likelihood ratio; NPV, negative predictive value; NUC, nucleos(t)ide analogue; Peg-IFN, peginterferon; PPV, positive predictive value.